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Figure. Signiﬁcant correlation between pulmonary artery pressure and cardiac iron.Ă
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S20Conclusion: All patients with transfusion dependent thalassaemia major
should be screened with a cardiac MRI for iron overload from the age of 7
years as serum ferritin done serially alone does not detect tissue iron
deposition. Aggressive chelation with the addition of deferiprone which
acts synergistically with deferasirox or desferrioxamine must be
commenced to reduce the incidence of cardiomyopathy in these patients
despite a low serum ferritin value. This is the ﬁrst comprehensive study of
cardiac iron in India and we plan to follow up this cohort annually to
evaluate the outcome of the intervention with serial cardiac MRI.
RBC-1_V1.3
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Background: Pancytopenia is a disorder in which all three major formed
elements of blood (red blood cells, white blood cells and platelets) are
decreased in number.Relevance of the study lies in the timely interven-
tion for the causes of pancytopenia which can either bring about a
complete cure or at least a remission from the disease entity. In India not
many studies have been done on this topic especially in pediatric age
group so the present study has been undertaken to evaluate the various
causes of pancytopenia, their clinical proﬁle and outcome.
Methods: This was a prospective observational study of 81 patients aged
between 1 month to 15 years admitted to Department of Pediatrics of King
George Medical University, Lucknow during August 2015 to July 2016 with
Hb<10g/dl, TLC<4000/mm3 and platelets<1 lakh/mm3. Patients under-
going/already undergone chemotherapy and radiotherapy were exclu-
ded.After informed consent, a detailed medical history, physical
examination, complete blood counts, anaemiaworkup, viral markers, bone
marrow examination was done along with transfusion records, treatment
received and outcomes were analysed.
Results: The bulk of patients were from rural background (87%).The mean
age at presentationwas 74months (range 1-180month) withMale:Female
e 2.8:1.
The most common clinical presentations were fever (78%), pallor (67%),
bleeding manifestations (43%); past h/o jaundice (5%) and pesticide
exposure (8%); hepatomegaly (56%) splenomegaly (42%) Lymphadenop-
athy (22%) and knuckle hyperpigmentation (14%).
The haematological parameters showed mean haemoglobin level: 4.9 gm/
dL, WBC: 2676/mm3, ANC: 1009/mm3, platelet: 43700/mm3, MCV:85.5
MCH: 30.5 RDW: 23.5 B12 487.7 Folate 12.3 Ferritin 777 s.Iron 179.8 .PNH
clone was present in 2.1%, Parvo B19 in 6% and EBV in 7% of patients.
5 patients (6%) were lost to follow up or expired before any treatment was
initiated.
Most common causes of pancytopenia found in our study were
Aplastic Anemia (49%), Acute leukemia (27%) and Megaloblastic/Nutritional (18%). Infections (9%) and hypersplenism (6%) etc accounted for
the rest.
All patients with megaloblastic anemia survived despite no trans-
fusions. But patients with very severe Aplastic Anemia and hemato-
logical malignancies had worse outcomes despite ATG courses ;
multiple transfusions and induction chemotherapy respectively.Patient
with Kala Azar, chronic Malaria infections and hypersplenism survived
after appropriate treatment.Also hospital stay was prolonged for leu-
kemias and Aplastic Anemia.
Conclusion: The etiology of pancytopenia varies widely ranging from
transient marrow viral suppression, drugs etc to marrow inﬁltration by
life-threatening malignancy.The severity of pancytopenia and the under-
lying pathology determine the management and prognosis of the patients
.Hence such studies will help in planning the diagnostic and therapeutic
approach in patients with pancytopenia and curtailing delays to reduce
multiple transfusions, pre-treatment infections and overall morbidity and
mortality associated with entity of Pancytopenia.
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Introduction: The Last three decades have witnessed profound changes in
the management of patients with thalassemia major. Regular and periodic
blood transfusion being the main stay of treatment results in iron overload
thus necessitating need for iron chelation. At present three iron chelators
namely, Desferrioxamine, Defriprone and deﬁrasirox are in use alone or in
combinations. Since the iron chelators are required to be given for the life-
time they also cause adverse events which are range from trivial to life
threatening.
Aims: To identify and manage adverse drug events due to iron chelating
drugs experienced by thalassemic patients.
Material and methods: This is an observational study done during 1st
January to 30th June 2016 in Thalassemia Day Care Centre of SMGS hospital,
Govt. Medical College Jammu. All the adverse events were recorded on a
pretestedproformaandwerevalidatedonNaranjo causalityassessmentscale.
Results: Of the 280 patients with the age ranging from 6 months to 53
years registered with Thalassemia Day Care Centre SMGS hospital Govt.
Medical College Jammu only 180 attended regular fortnightly follow up
clinics. Out of these 180 patients 168 are on Iron chelation drugs (129 on
Defriprone, 24 on Deﬁrasirox, 8 on Defriprone + Desferrioxamine, 4 on
Desferrioxamine and 3 on Defriprone + Desferrixamin) Out of 32 events
observed during the course of study 21 (65.62%) were due to Defriprone,
8 (25%) due to Deferasirox and 3 (9.38%) due to Desfferioxamine. Out of
21 events due to Defriprone 12 (57.14%) were gastrointestinal symp-
toms, 5 (23.8%) arthropathy, 2 (9.5%) Neutropenia and 2 (9.5%) throm-
bocytopenia. All 8 (100%) events due to Deferasirox were
gastrointestinal symptoms. 2 (66.66%) events with desferrioxamine
were local reactions and 1 (33.33%) was encephalitis. On Naranjo Cas-
uality scale 5/32 was deﬁnite while as 24 /32 was probable and 3/32
were possible. While 9 were mild reactions, 4 were severe reactions and
19 were moderate reactions.
Conclusion: Majority of adverse events were observed with Defriprone
followed byDeferasirox. Although least adverse eventswere observedwith
desferrioxamine, but adverse events with deferasirox were least severe.
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